{"id":"W4220925708","doi":"10.1136/rmdopen-2021-002138","title":"Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study","year":2022,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Cilag; Regeneron Pharmaceuticals; UCB Pharma; Ablynx; Gilead Sciences; Eisai; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Certolizumab pegol; Axial spondyloarthritis; Radiography; Term (time); Internal medicine; Sacroiliitis; Ankylosing spondylitis; Medical physics; Physical therapy; Radiology; Nuclear medicine; Adalimumab; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001531156,0.0002689229,0.0009226303,0.00009496247,0.0003375135,0.00003437489,0.000229967,0.00004403185,0.0001302464],"category_scores_gemma":[0.00006455618,0.000166295,0.0001306421,0.0002959079,0.0001673857,0.0001094298,0.000428986,0.0002203774,0.000003108248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001496906,"about_ca_system_score_gemma":0.0001029636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004836709,"about_ca_topic_score_gemma":0.006840731,"domain_scores_codex":[0.9978178,0.0002615471,0.0006444316,0.0005806111,0.0004234859,0.0002721138],"domain_scores_gemma":[0.998629,0.000390094,0.0002432186,0.0005562639,0.0000647179,0.0001167226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05480728,0.009477875,0.9084665,0.000003042816,0.001293842,0.000766298,0.002498491,5.799872e-7,3.677586e-7,0.000002201672,0.00003021337,0.02265328],"study_design_scores_gemma":[0.1764768,0.01536322,0.8053548,0.00005951375,0.000396977,0.00001425867,0.002054437,0.000001882936,0.000002502378,0.000004425797,0.0001419709,0.00012913],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921064,0.0001996089,4.790514e-7,0.0003969087,0.0001528898,0.00470663,0.002094789,0.00001068415,0.0003316423],"genre_scores_gemma":[0.9986793,0.0003275106,0.00003383847,0.00004448434,0.00004031815,0.0002371817,0.0004852522,0.00002800838,0.000124144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1216696,"threshold_uncertainty_score":0.7311689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02632555762703032,"score_gpt":0.3369773064063954,"score_spread":0.3106517487793651,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}